sitravatinib experimental drug treatment cancer small molecule inhibitor multiple tyrosine sitravatinib developed mirati ongoing phase ii trials include trial combination trial nonsmall cell lung combination trial nivolumab renal cell sitravatinib evaluated ongoing trials patients advanced nonsmall cell lung cancer including combination trial nivolumab resistant checkpoint inhibitor therapy certain patients na√Øve checkpoint inhibitor httpsenwikipediaorgwikisitravatinib